Organization & Developments: Portola

Parents

2017: FDA OKs Portola's anticoagulant betrixaban; shares up 1% - Portola Pharmaceuticals (NASDAQ:PTLA)
2017: Portola Pharmaceuticals: What The AndexXa Approval Delay Means? - Portola Pharmaceuticals (NASDAQ:PTLA)
2018: FDA Approval of Portola Drug Puts Firm in Line for $100M Payday
2018: Reader Inquiry: After Approval Is Portola Pharmaceuticals A Buy?_seekingalpha.com
2020: Portola Pharmaceuticals - This Name You Haven't Heard Of Is The Next Big COVID-19 Company
Company has global development and commercialization agreements with two of the world’s leading pharmaceutical companies collectively valued at about $1 billion in upfront and milestone payments plus double-digit royalties on future sales.
Leaders in the fields of platelet biology and thrombosis.
Organization & Developments: Portola (Archives 2010-2016)
Portola develops innovative therapeutics based on targets with established proofs of concept that are designed to provide significant advances over current treatments for cardiovascular disease and inflammation.
Portola: Pipeline
PRT064445, which is designed to reverse anticoagulant activity in patients who have been administered Factor Xa inhibitors prior to surgery or to stop major bleeds.